Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients-Reference-Cited by-同舟云学术

Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients

Published:2005-06-15 Issue:11 Volume:79 Page:1477-1483
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Wiltshire Hugh,Paya Carlos V.,Pescovitz Mark D.,Humar Atul,Dominguez Edward,Washburn Kenneth,Blumberg Emily,Alexander Barbara,Freeman Richard,Heaton Nigel,Zuideveld Klaas P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference26 articles.

1. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.;Sia;Clin Microbiol Rev,2000

2. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.;Pescovitz;Antimicrob Agents Chemother,2000

3. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients.;Gane;Lancet,1997

4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.;Flechner;Transplantation,1998

5. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.;Paya;J Infect Dis,2002

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus in haematopoietic cell transplantation - The troll is still there;Best Practice & Research Clinical Haematology;2024-09

2. Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy;Antimicrobial Agents and Chemotherapy;2024-08-28

3. The pharmacokinetics of ganciclovir during prolonged intermittent kidney replacement therapy in a cardiac transplant recipient;Journal of Chemotherapy;2024-08-26

4. Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials;Clinical Pharmacology & Therapeutics;2024-08-09

5. Contribution of Adsorption and Hematocrit Levels to Ganciclovir Clearance in an <i>in Vitro</i> Continuous Hemodiafiltration Model;Biological and Pharmaceutical Bulletin;2024-07-31